An attempt to determine the clinical significance of anti-Bga was performed by transfusing 51Cr-labelled red blood cells (RBC) from HLA-B7 positive donors to four patients who had histories of anti-Bga. Pre-and post-transfusion samples showed no change in antibody titer scores, haptoglobin or complement levels. Three of the patients were then transfused with 51Cr-labelled RBC from HLA-B7 negative donors and the half-life (T50Cr) of both were compared. Although low, the T50Cr of HLA-B7 incompatible RBC appeared to be similar to the T50Cr of HLA-B7 compatible RBC.
Introduction
In order to evaluate the possibility of implementing a Type and Screen system in Kyoto, Japan, a retrospective study was undertaken of 31,490 crossmatches performed on 4,276 patient samples by our reference laboratory from January 1,1985 to December 31,1987. Of 2,912 samples tested in which the patient had no antibody history and a negative antibody screening, there was only one case (0.03%) in which an incompatible crossmatch was detected in the antihumanglobulin (AHG) phase1. The incompatibility was due anti-Bga. The 12th edition of the American Association of Blood Banks' Standards states that if no clinically significant antibodies are detected and there is no record of such antibodies, only the test methods that demonstrate ABO incompatibility are required (immediate-spin crossmatch)2). In the case of a type and screen system, the immediate-spin crossmatch is the recommended replacement for the traditional crossmatch which includes an AHG phase3~. Reports assessing transfusion safety after immediate-spin crossmatch indicate the risk appears to be low4. But a search of available literature revealed conflicting reports concerning the clinical significance of anti-Bga9)-13).
Morton et al. showed that Bga, Bgb and Bga red cell antigens are identical to B7, B17 and A28 HLA determinants14)15). In order to determine the clinical significance of anti-Bga, our laboratory, in conjunction with the Kyoto First Red Cross Hospital, performed 51Cr RBC survival studies on four patients whose sera contained anti-Bga. Phase one of the study consisted of transfusing 51Cr-labelled RBC from HLA-B7 incompatible donors to all four patients. During the second phase of the study, three of the four patients were transfused with 51Cr-labelled RBC from HLA-B7 compatible donors.
Materials and Methods
Standard serological techniques for antibody screening, identification and crossmatching were followed according to procedures described in the 9th edition of the American Association of Blood Banks' technical manuall6i.
Lymphocyte serological testing was performed by the standard micro-lymphocytotoxicity test (LCT), and the antihumanglobulin-LCT (AHG-LCT) using antihumanglobulin-light-chain (K) was used17)18).
51Cr-labelling was performed according to method C, as recommended by the International Committee for Standardization in Haematology19). Ascorbic acid, which reduces hexavalent Cr to trivalent Cr and thus not taken up by red cells, is added to ACD blood instead of washing the red cells after incubation with 51Cr20).
Blood samples for determination of complement (CH50) and haptoglobin (Hp) levels were taken 10 minutes before and 1 and 20 hours after infusion of 51Cr-labelled red cells. CH50 determination was performed according to the procedure described by Mayer21) and Hp levels according to Hirabayashi22).
All patients studied were transfused with leukocyte-poor red blood cells (LPRC) which were prepared by filtering ("Imugard", Terumo, Tokyo) freshly drawn (1-2 days old) packed red cells. This procedure removed 92% to 95% of the leukocytes.
Red cell panels including Bg(a+) cells were provided by Gamma Biologics (Kainos Laboratories Inc, Tokyo), Ortho Diagnostic Systems KK (Tokyo) and Immucor Biologic (Sanko Junyaku Co Ltd, Tokyo). Table 1 details the clinical and serological data of all four patients involved in this study. Because o histories of febrile transfusion reactions due to multispecif is HLA antibodies, each patient had received multiple transfusions of LPRCs and HLA-matched single donor pheresis platelets prior to the start of the study. The HLA types and HLA crossmatch results of the donors that were 51Cr-labelled are listed in table   Table 1 Clinical and serological data of 4 patients involved in 51Cr-survival studies 
Discussion
The clinical significance of the antibodies to the Bg blood group has generated conflicting reports. In 1977, Silvergleid et a1. 10) transfused 51Cr-labelled RBC to crossmatch positive patients. They studied one case in which 92% RBC survival was observed 1 hour post-transfusion, and determined that anti-Bg was clinically insignificant. The authors did state that more studies were needed in order to confirm that Bg antibodies are not hemolytic. Baldwin et al. 11 reported a case of shortened RBC survival in a patient whose only detectable antibody was anti-Bga, but did not believe it was due to the antibody because it was always detectable by routine serologic techniques and none of the transfused units were incompatible in vitro. However, in that paper the HLA-B7 typings of transfused units were not reported. In 1984, Panzer et al. 12) described a study in which shortened mean life-span of RBC is to be expected when anti-Bga is present. Mollison231 disagrees with Panzer's interpretation of the data and states that in four of the six cases presented, survival was probably normal and the method used to calculate mean life-span was incorrect. In a separate report, Panzer et al. 13i further describes four patients who received HLA-B7 incompatible RBC and who all suffered hemolytic transfusion reactions and shortened survival of 51Cr-labelled RBC. A rise in serum lactic dehydrogenase and a fall in haptoglobin were also observed.
In the present study, RBC from both HLA-B7 compatible and incompatible donors were 51Cr-labelled and transfused to patients who had anti-Bga. All four patients had below normal survival of both HLA-B7 compatible and incompatible RBC, but there was no other data to suggest in vivo red cell destruction occured. Pre-and post-transfusion haptoglobin and complement levels remained the same and no increase in antibody titer was observed. The apparent shortened RBC survival may have been due to the diseased states of the patients. Until a larger study can be conducted which includes survival studies of HLA-B7 compatible and incompatible red blood cells transfused to hematological patients and healthy donors who have anti-Bga, the transfusion service must evaluate each patient's transfusion history to determine the likelihood of normal red blood cell survival. If the proper increment rise is not observed in a patient after transfusion, then consideration should be given to survival studies performed with HLA-B7 compatible and incompatible red blood cells.
